Response to drug treatment in newly diagnosed epilepsy: A pilot study of 1H NMR- and MS-based metabonomic analysis

Epilepsy Research

Volumn 88, Issue 2-3, 2010, Pages 189-195

  Al Zweiri, Muhammed ^a   Sills, Graeme J ^b   Leach, John Paul ^b   Brodie, Martin J ^b   Robertson, Chris ^a   Watson, David G ^a   Parkinson, John A ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

Antiepileptic drugs; Mass spectrometry; Metabonomics; Nuclear magnetic resonance spectroscopy; Principal components analysis; Response to treatment

Indexed keywords

BIOLOGICAL MARKER; ETIRACETAM; LAMOTRIGINE; TOPIRAMATE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; METABOLISM; OUTCOME ASSESSMENT; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; BIOLOGICAL MARKERS; EPILEPSY; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; METABOLOMICS; MIDDLE AGED; PILOT PROJECTS; PRINCIPAL COMPONENT ANALYSIS; TREATMENT OUTCOME;

EID: 75849136402     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2009.11.005     Document Type: Article

References (27)

1. 1H NMR metabonomics as a prognostic and diagnostic tool. Exp. Rev. Mol. Diagn. 7 (2007) 761-773
2. Al Zweiri M., Watson D.G., Robertson C., Sills G.J., and Parkinson J.A. Comparison of different water-miscible solvents for the preparation of plasma and urine samples in metabolic profiling studies. Talanta 74 (2008) 1060-1065
3. Beckonert O., Keun H.C., Ebbels T.M.D., Bundy J., Holmes E., Lindon J.C., and Nicholson J.K. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat. Protoc. 2 (2007) 2692-2703
4. 1H NMR spectroscopy of blood serum. Analyst 128 (2003) 814-818
5. Beger R.D., Schnackenberg L.K., Holland R.D., Li D., and Dragan Y. Metabonomic models of human pancreatic cancer using 1D proton NMR spectra of lipids in plasma. Metabolomics 2 (2006) 125-134
6. Bogdanov M., Matson W.R., Wang L., Matson T., Saunders-Pullman R., Bressman S.S., and Flint Beal M. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 131 (2008) 389-396
7. 1H NMR-based metabonomics. Nat. Med. 8 (2002) 1439-1444
8. Brodie M.J. Response to antiepileptic drug therapy: winners and losers. Epilepsia 46 Suppl. 10 (2005) 31-32
9. Clayton T.A., Lindon J.C., Cloarec O., Antti H., Charuel C., Hanton G., Provost J.-P., Le Net J.-L., Baker D., Walley R.J., Everett J.R., and Nicolson J.K. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440 (2006) 1073-1077
10. Crockford D.J., Holmes E., Lindon J.C., Plumb R.S., Zirah S., Bruce S.J., Rainville P., Stumpf C.L., and Nicholson J.K. Statistical heterospectroscopy, and approach to the integrated analysis of NMR and UPLC-MS data sets: application in metabonomic toxicology studies. Anal. Biochem. 78 (2006) 363-371
11. Devinsky O. Patients with refractory seizures. N. Engl. J. Med. 340 (1999) 1565-1570
12. Hitiris N., Mohanraj R., Norrie J., Sills G.J., and Brodie M.J. Predictors of pharmacoresistant epilepsy. Epilepsy Res. 75 (2007) 192-196
13. Kwan P., and Brodie M.J. Early identification of refractory epilepsy. N. Engl. J. Med. 342 (2000) 314-319
14. Lindon J.C., Holmes E., and Nicholson J.K. Metabonomics techniques and applications to pharmaceutical research & development. Pharm. Res. 23 (2006) 1075-1088
15. Mohanraj R., and Brodie M.J. Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur. J. Neurol. 13 (2006) 277-282
16. Nebert D.W., and Vesell E.S. Can personalized drug therapy be achieved? A closer look at pharmaco-metabonomics. Trends Pharmacol. Sci. 27 (2006) 580-586
17. 13C NMR spectroscopy of human blood plasma. Anal. Chem. 67 (1995) 793-811
18. Nicholson J.K., Lindon J.C., and Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29 (1999) 1181-1189
19. Nicholson J.K., Connelly J., Lindon J.C., and Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. 1 (2002) 153-161
20. Nicholson J.K., Holmes E., Lindon J.C., and Wilson I.D. The challenges of modelling mammalian biocomplexity. Nat. Biotechnol. 22 (2004) 1268-1274
21. 1H-NMR-based metabonomics. Int. J. Cancer 113 (2005) 782-788
22. Ramachandran V., and Shorvon S.D. Clues to the genetic influences of drug responsiveness in epilepsy. Epilepsia 44 Suppl. 1 (2003) 33-37
23. Salek R.M., Maguire M.L., Bentley E., Rubtsov D.V., Hough T., Cheeseman M., Nunez D., Sweatman B.C., Haselden J.N., Cox R.D., Connor S.C., and Griffin J.L. A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human. Physiol. Genomics 29 (2007) 99-108
24. Schmidt D., and Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 46 (2005) 858-877
25. Sisodiya S.M. Genetics of drug resistance in epilepsy. Curr. Neurol. Neurosci. Rep. 5 (2005) 307-311
26. Szoeke C.E.I., Newton M., Wood J.M., Goldstein D., Berkovic S.F., O'Brien T.J., and Sheffield L.J. Update on pharmacogenetics in epilepsy: a brief review. Lancet Neurol. 5 (2006) 189-196
27. Weckwerth W., and Morgenthal K. Metabolomics: from pattern recognition to biological interpretation. Drug Discov. Today 10 (2005) 1551-1558